After anti-HER2 treatment, in tumours exhibiting HER2 amplification, there would be a downregulation in the release of cytokines, including CCL2, CCL21, VEGF, and CXCL1, which leads to an amelioration of the immunosuppressive factors within the tumour microenvironment20. The gene discussed is VEGFA; the disease is neoplasm.